# Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Source: https://onco.cc/trials/nct05702229/  
OnCo record `nct05702229` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Rilvegostomig, CAPOX (capecitabine, oxaliplatin) and Capecitabine in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.

## Summary

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma is a phase 2 interventional study registered as NCT05702229 by AstraZeneca, with 163 participants planned, started 2023-01-16 and due to reach its primary completion in 2027-11-30. Interventions recorded: Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901 and 5-Fluorouracil.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05702229
- Phase: 2
- Setting: An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Sponsor: AstraZeneca
- Enrolled: 163

## Sources

- ClinicalTrials.gov NCT05702229: https://clinicaltrials.gov/study/NCT05702229

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05702229.json